Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.

Article  PubMed  Google Scholar 

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.

Article  PubMed  Google Scholar 

Cortesi L, Rugo HS, Jackisch C. An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol. 2021;16(3):255–82.

Article  PubMed  PubMed Central  Google Scholar 

Tung NM, Boughey JC, Pierce LJ, et al. Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology guideline. J Clin Oncol. 2020;38(18):2080–106.

Article  CAS  PubMed  Google Scholar 

Dubsky P, Jackisch C, Im SA, et al. BRCA genetic testing and counseling in breast cancer: how do we meet our patients’ needs? NPJ Breast Cancer. 2024;10(1):77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Offit K, Tkachuk KA, Stadler ZK, et al. Cascading after peridiagnostic cancer genetic testing: an alternative to population-based screening. J Clin Oncol. 2020;38(13):1398–408.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. Version 2.2025. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed 12 December 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Beitsch PD, Whitworth PW, Hughes K, et al. Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol. 2019;37(6):453–60.

Article  PubMed  Google Scholar 

Yadav S, Hu C, Hart SN, et al. Evaluation of germline genetic testing criteria in a hospital-based series of women with breast cancer. J Clin Oncol. 2020;38(13):1409–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Geyer CE Jr, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer. Ann Oncol. 2022;33(12):1250–68.

Article  CAS  PubMed  Google Scholar 

Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Eng J Med. 2021;384(25):2394–405.

Article  CAS  Google Scholar 

AstraZeneca. Lynparza® (olaparib) Prescribing information. http://www.azpicentral.com/pi.html?product=lynparza_tb. Accessed Mar 10 2025.

AstraZeneca. Lynparza® (olaparib). Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Accessed Mar 10 2025.

AstraZeneca. LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial. https://www.astrazeneca-us.com/media/press-releases/2024/lynparza-demonstrated-clinically-meaningful-prolonged-survival-benefit-in-early-breast-cancer-in-olympia-phase-iii-trial.html. Accessed Mar 10 2025.

Bedrosian I, Somerfield MR, Achatz MI, et al. Germline testing in patients with breast cancer: ASCO—Society of Surgical Oncology guideline. J Clin Oncol. 2024;42(5):584–604.

Article  PubMed  Google Scholar 

Manahan ER, Kuerer HM, Sebastian M, et al. Consensus guidelines on genetic testing for hereditary breast cancer from the American Society of Breast Surgeons. Ann Surg Oncol. 2019;26(10):3025–31.

Article  PubMed  PubMed Central  Google Scholar 

Olaya W, Esquivel P, Wong JH, et al. Disparities in BRCA testing: when insurance coverage is not a barrier. Am J Surg. 2009;198(4):562–5.

Article  PubMed  Google Scholar 

Yip CH, Evans DG, Agarwal G, et al. Global disparities in breast cancer genetics testing, counselling and management. World J Surg. 2019;43(5):1264–70.

Article  CAS  PubMed  Google Scholar 

Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817–26.

Article  CAS  PubMed  Google Scholar 

Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kalinsky K, Barlow WE, Gralow JR, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726–34.

Article  CAS  PubMed  Google Scholar 

Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55–65.

Article  CAS  PubMed  Google Scholar 

Halpern N, Sonnenblick A, Uziely B, et al. Oncotype DX recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer. Int J Cancer. 2017;140(9):2145–9.

Article  CAS  PubMed  Google Scholar 

McAndrew NP, Maxwell KN, Stopfer J, et al. Oncotype DX scores in BRCA1 and BRCA2 associated breast cancer. J Clin Oncol. 2015;33(15 Suppl.):541.

Article  Google Scholar 

Shah PD, Patil S, Dickler MN, Offit K, Hudis CA, Robson ME. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: differences based on germline mutation status. Cancer. 2016;122(8):1178–84.

Article  CAS  PubMed  Google Scholar 

Casasanta N, Kipnis ST, Linville L, et al. Relationship between hereditary cancer syndromes and Oncotype DX recurrence score. Clin Breast Cancer. 2020;20(2):125–30.

Article  CAS  PubMed  Google Scholar 

Lewin R, Sulkes A, Shochat T, et al. Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations. Breast Cancer Res Treat. 2016;157(3):511–6.

Article  CAS  PubMed  Google Scholar 

Birnbaum B, Nussbaum N, Seidl-Rathkopf K, et al. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research [preprint]. arXiv. 2020. arXiv:2001.09765. https://doi.org/10.48550/arXiv.2001.09765

Ma X, Long L, Moon S, Adamson BJS, Baxi SS. Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR [preprint]. medRxiv. 2023. https://doi.org/10.1101/2020.03.16.20037143

National Institutes of Health. Office of Intramural Research: Office of Human Subjects Research Protections. https://irbo.nih.gov/confluence/display/ohsrp/OHSRP. Accessed Mar 10 2025.

U.S. Department of Health and Human Services. November 21, 2019: Determination of exception for certain HHS-conducted or -supported cooperative research activities subject to the 2018 requirements. 2020. https://www.hhs.gov/ohrp/regulations-and-policy/single-irb-exception-determinations/november-2019-exception-determination/index.html. Accessed Mar 10 2025.

Namuche F, Ruiz RE, Morante Cruz ZD, Urrunaga D, Aguilar Cartagena A, Gomez Moreno HL. Ki67 as an important predictor for oncotype Dx recurrence score risk groups in early breast cancer. Ann Oncol. 2018;29(8):VIII68.

Article  Google Scholar 

Thakur SS, Li H, Chan AMY, et al. The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer. PLoS ONE. 2018;13(1):e0188983.

Article  PubMed  PubMed Central  Google Scholar 

Kurian AW, Ward KC, Abrahamse P, Hamilton AS, Katz SJ. Predicted chemotherapy benefit for breast cancer patients with germline pathogenic variants in cancer susceptibility genes. JNCI Cancer Spectr. 2020;5(1):pkaa083.

Article  PubMed  PubMed Central  Google Scholar 

Copson ER, Abraham JE, Braybrooke JP, et al. Expert UK consensus on the definition of high risk of recurrence in HER2-negative early breast cancer: a modified Delphi panel. Breast. 2023;72:103582.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blanter J, Zimmerman B, Tharakan S, Ru M, Cascetta K, Tiersten A. BRCA mutation association with recurrence score and discordance in a large oncotype database. Oncology. 2020;98(4):248–51.

Article